Emulsifiers Market Estimated to Reach $13.1 Billion by 2027 Globally, at a CAGR of 7.6%, says MarketsandMarkets™

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

Chicago, March 15, 2023 (GLOBE NEWSWIRE) — The global emulsifiers market size is projected to reach USD 13.1 billion by 2027 from USD 9.1 billion in 2022, at a CAGR of 7.6%, as per the recent study by MarketsandMarkets™. The rising need for emulsifiers in developing nations like India, China, Brazil, and others is due to the increased demand for processed food and beverages and the growth of the cosmetics and personal care industry. Also, the rising awareness of health and wellness is driving demand for natural and organic emulsifiers. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240653061 Browse in-depth TOC on “Emulsifiers Market” 251 – Market Data Tables 48 – Figures 260 – Pages List of Key Players in Emulsifiers Market: BASF SE (Germany) Archer Daniels Midland (ADM)...

Park Hotels & Resorts Inc. Announces First Quarter Dividend of $0.15 Per Share

Written by Customer Service on March 15, 2023. Posted in Dividend Reports And Estimates.

TYSONS, Va., March 15, 2023 (GLOBE NEWSWIRE) — Park Hotels & Resorts Inc. (NYSE: PK) (“Park” or the “Company”) announced today that the Company has declared a first quarter cash dividend of $0.15 per share of common stock. The dividend will be paid in cash on April 17, 2023 to stockholders of record as of March 31, 2023. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements related to Park’s current expectations regarding the performance of its business, financial results, liquidity and capital resources, including anticipated repayment of certain of the Company’s indebtedness, the completion...

Proterra Releases Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

BURLINGAME, Calif., March 15, 2023 (GLOBE NEWSWIRE) — Proterra Inc (NASDAQ: PTRA) today released its fourth quarter and full year 2022 financial results by posting them to its Investor Relations website. Please visit the Proterra Investor Relations website at ir.proterra.com to view the fourth quarter and full year 2022 financial results and letter to shareholders. A conference call will be held at 2:00pm Pacific Daylight Time on Wednesday, March 15, 2023 to review financial results. A live audio webcast of the conference call will be available on Proterra’s Investor Relations website at ir.proterra.com. About ProterraProterra is a leader in the design and manufacture of zero-emission electric transit vehicles and EV technology solutions for commercial applications. With industry-leading durability and energy efficiency based...

Fluent Announces Fourth Quarter and Full-Year 2022 Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Revenue of $84.7 million for Q4 2022 and $361.1 million for FY 2022 Net loss of $67.5 million for Q4 2022 and $123.3 million for FY 2022 Gross profit (exclusive of depreciation and amortization) of $20.0 million for Q4 2021 and $93.6 million for FY 2022 Media margin of $23.7 million for Q4 2022 and $110.0 million for FY 2022 Adjusted EBITDA of $2.7 million for Q4 2022 and $22.7 million for FY 2022 Adjusted net loss of $0.8 million for Q4 2022 and adjusted net income of $5.8 million for FY 2022 NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported results for the fourth quarter and fiscal year ended December 31, 2022. Donald Patrick, Fluent’s Chief Executive Officer, commented, “Our results for the fourth quarter reflect the...

Regimen Equity Partners’ portfolio company, Plastifab, has acquired Marchel Industries, broadening Plastifab’s capabilities and accelerating its growth in the United States

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) — Regimen Equity Partners Inc. (“Regimen”) is pleased to announce the acquisition of Marchel Industries Inc. (“Marchel” or “the Company”) by its portfolio company, Plastifab Industries, Inc. (“Plastifab”). Marchel represents a highly synergistic and strategic acquisition that will bolster Plastifab’s presence in the US market in addition to broadening Plastifab’s service portfolio by adding injection molding capabilities to better serve Plastifab’s diverse customer set. Matt Pitts, will continue with Marchel as a partner, leading the day-to-day at the Company, with strategic direction and oversight coming from Plastifab and Regimen. Located in Spartanburg, South Carolina, Marchel is a full-service plastic injection molding and machining company. The Company is operated...

Superior Group of Companies Reports Fourth Quarter Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

SEMINOLE, Fla., March 15, 2023 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its fourth quarter results for 2022. – Total Sales Increased 5% Over Prior Year Quarter to $149 Million –– Net Income of $2 Million, versus $4 Million in Prior Year Quarter –– Adjusted Net Loss of ($0.9) Million, versus Adjusted Net Income of $5 Million in Prior Year Quarter –– Adjusted EBITDA of $3 Million, versus $8 Million in Prior Year Quarter –– Provides Initial 2023 Guidance – Fourth Quarter Results For the fourth quarter, net sales increased 5% to $148.6 million compared to fourth quarter 2021 net sales of $142.0 million. Net income was $2.2 million or $0.14 per diluted share compared to net income of $4.4 million or $0.27 per diluted share in the fourth quarter of 2021. During the fourth quarter,...

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product Revenues, including FYCOMPA, of between $375 Million and $385 Million Recently Acquired Patents Further Strengthens FIRDAPSE Long-Term Commercial Potential to 2037 Actively Pursuing Opportunities to Further Diversify our Product Portfolio Ended 2022 with Cash and Cash Equivalents of $298 Million Company to Host a Conference Call and Webcast on Thursday, March 16, 2023, at 8:30 AM ET CORAL GABLES, Fla., March 15, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused...

Rapid7 Acquires Minerva Labs to Extend Leading Managed Detection and Response Service with Ransomware Prevention Technology

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

Minerva’s robust technology and talented engineering team extend Rapid7’s end-to-end managed threat detection and orchestration capabilities from the endpoint to the cloud BOSTON, March 15, 2023 (GLOBE NEWSWIRE) — Rapid7, Inc. (NASDAQ: RPD), a leader in cloud risk and threat detection, today announced it has acquired Minerva Labs, Ltd., a leading provider of anti-evasion and ransomware prevention technology. Today, Rapid7’s Managed Detection and Response (MDR) services provide customers elevated detection and response capabilities across their cloud, on-premise and extended attack surfaces. With this acquisition, Rapid7 will further extend its leading managed threat detection capabilities with the ability to orchestrate advanced ransomware prevention. These new capabilities will seamlessly extend MDR across cloud resources, traditional...

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023 First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline data in healthy volunteers expected in 2H 2023 Ended 2022 with $574.2 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for...

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced its fourth quarter and full year ended December 31, 2022, financial results and provided initial 2023 revenue guidance. Fourth Quarter and Full Year Highlights Total revenue of $12.4 million in the fourth quarter of 2022, an increase of 22% over the fourth quarter of 2021. Core business revenues grew 4% in the fourth quarter of 2022, with revenue growth from cell therapy...

Day: March 15, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice